Controversies in Liver Transplantation for Hepatitis C

Sandeep Mukherjee, Michael F. Sorrell

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Hepatitis C is one of the most common indications for liver transplantation in the United States, accounting for approximately 40%-45% of all liver transplants. Unfortunately, recurrent disease is universal in patients who are viremic before transplantation. This can lead to cirrhosis in at least 25% of patients 5 years after liver transplantation, and recurrent hepatitis C is now emerging as an important but occasionally contentious indication for retransplantation. Several attempts have been undertaken to identify patients at high risk for severe recurrent disease who may benefit from treatment, but unfortunately antiviral therapy frequently is ineffective and often is associated with numerous side effects. Although we have made significant strides in understanding the natural history of this disease in nontransplant patients, this does not hold true for the transplant population in which several uncertainties covering virtually the entire spectrum of liver transplantation persist. Despite these concerns, on a more practical level, it is usually only in the postoperative setting that clinicians truly can assess the impact of their interventions on the natural history of recurrent hepatitis C, for example, by adjusting immunosuppression or prescribing antiviral therapy. Preoperative and perioperative (including donor) factors often are outside the control of hepatologists and transplant surgeons. This review is not an inclusive review of the literature but summarizes what we believe are the more controversial topics of this disease.

Original languageEnglish
Pages (from-to)1777-1788
Number of pages12
JournalGastroenterology
Volume134
Issue number6
DOIs
StatePublished - May 2008
Externally publishedYes

Fingerprint

Hepatitis C
Liver Transplantation
Transplants
Antiviral Agents
Immunosuppression
Uncertainty
Fibrosis
Therapeutics
Transplantation
Tissue Donors
Liver
Population

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Controversies in Liver Transplantation for Hepatitis C. / Mukherjee, Sandeep; Sorrell, Michael F.

In: Gastroenterology, Vol. 134, No. 6, 05.2008, p. 1777-1788.

Research output: Contribution to journalArticle

Mukherjee, Sandeep ; Sorrell, Michael F. / Controversies in Liver Transplantation for Hepatitis C. In: Gastroenterology. 2008 ; Vol. 134, No. 6. pp. 1777-1788.
@article{abfda6e0a12542f0a1746ac9238f13f4,
title = "Controversies in Liver Transplantation for Hepatitis C",
abstract = "Hepatitis C is one of the most common indications for liver transplantation in the United States, accounting for approximately 40{\%}-45{\%} of all liver transplants. Unfortunately, recurrent disease is universal in patients who are viremic before transplantation. This can lead to cirrhosis in at least 25{\%} of patients 5 years after liver transplantation, and recurrent hepatitis C is now emerging as an important but occasionally contentious indication for retransplantation. Several attempts have been undertaken to identify patients at high risk for severe recurrent disease who may benefit from treatment, but unfortunately antiviral therapy frequently is ineffective and often is associated with numerous side effects. Although we have made significant strides in understanding the natural history of this disease in nontransplant patients, this does not hold true for the transplant population in which several uncertainties covering virtually the entire spectrum of liver transplantation persist. Despite these concerns, on a more practical level, it is usually only in the postoperative setting that clinicians truly can assess the impact of their interventions on the natural history of recurrent hepatitis C, for example, by adjusting immunosuppression or prescribing antiviral therapy. Preoperative and perioperative (including donor) factors often are outside the control of hepatologists and transplant surgeons. This review is not an inclusive review of the literature but summarizes what we believe are the more controversial topics of this disease.",
author = "Sandeep Mukherjee and Sorrell, {Michael F.}",
year = "2008",
month = "5",
doi = "10.1053/j.gastro.2008.02.035",
language = "English",
volume = "134",
pages = "1777--1788",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Controversies in Liver Transplantation for Hepatitis C

AU - Mukherjee, Sandeep

AU - Sorrell, Michael F.

PY - 2008/5

Y1 - 2008/5

N2 - Hepatitis C is one of the most common indications for liver transplantation in the United States, accounting for approximately 40%-45% of all liver transplants. Unfortunately, recurrent disease is universal in patients who are viremic before transplantation. This can lead to cirrhosis in at least 25% of patients 5 years after liver transplantation, and recurrent hepatitis C is now emerging as an important but occasionally contentious indication for retransplantation. Several attempts have been undertaken to identify patients at high risk for severe recurrent disease who may benefit from treatment, but unfortunately antiviral therapy frequently is ineffective and often is associated with numerous side effects. Although we have made significant strides in understanding the natural history of this disease in nontransplant patients, this does not hold true for the transplant population in which several uncertainties covering virtually the entire spectrum of liver transplantation persist. Despite these concerns, on a more practical level, it is usually only in the postoperative setting that clinicians truly can assess the impact of their interventions on the natural history of recurrent hepatitis C, for example, by adjusting immunosuppression or prescribing antiviral therapy. Preoperative and perioperative (including donor) factors often are outside the control of hepatologists and transplant surgeons. This review is not an inclusive review of the literature but summarizes what we believe are the more controversial topics of this disease.

AB - Hepatitis C is one of the most common indications for liver transplantation in the United States, accounting for approximately 40%-45% of all liver transplants. Unfortunately, recurrent disease is universal in patients who are viremic before transplantation. This can lead to cirrhosis in at least 25% of patients 5 years after liver transplantation, and recurrent hepatitis C is now emerging as an important but occasionally contentious indication for retransplantation. Several attempts have been undertaken to identify patients at high risk for severe recurrent disease who may benefit from treatment, but unfortunately antiviral therapy frequently is ineffective and often is associated with numerous side effects. Although we have made significant strides in understanding the natural history of this disease in nontransplant patients, this does not hold true for the transplant population in which several uncertainties covering virtually the entire spectrum of liver transplantation persist. Despite these concerns, on a more practical level, it is usually only in the postoperative setting that clinicians truly can assess the impact of their interventions on the natural history of recurrent hepatitis C, for example, by adjusting immunosuppression or prescribing antiviral therapy. Preoperative and perioperative (including donor) factors often are outside the control of hepatologists and transplant surgeons. This review is not an inclusive review of the literature but summarizes what we believe are the more controversial topics of this disease.

UR - http://www.scopus.com/inward/record.url?scp=42949133318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42949133318&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2008.02.035

DO - 10.1053/j.gastro.2008.02.035

M3 - Article

VL - 134

SP - 1777

EP - 1788

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 6

ER -